Well-differentiated epithelial thyroid cancer management in the Asia Pacific region: A report and clinical practice guideline

Thyroid

Volumn 16, Issue 5, 2006, Pages 461-469

  Sundram, Felix ^a   Robinson, Bruce G ^b   Kung, Annie ^c   Lim Abrahan, Mary Anne ^d   Bay, Nguyen Quang ^e   Chuan, Loh Keh ^f   Chung, Jae Hoon ^g   Huang, Shih Ming ^h   Hsu, Li Cho ⁱ   Kamaruddin, Norazmi ^j   Cheah, Wei Keat ^k   Kim, Won Bae ^l   Koong, Sung Soo ^m   Lin, Hong Da ⁿ   Mangklabruks, Ampica ^o   Paz Pacheco, Elizabeth ^d   Rauff, Abu ^k   Ladenson, Paul W ^p,q  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^e Service de Rhumatologie   (Viet Nam)

^f TAN TOCK SENG HOSPITAL   (Singapore)

^g Sungkyunkwan University School of Medicine   (South Korea)

^h BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

ⁱ NATIONAL YANG MING UNIVERSITY   (Taiwan)

^j UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

^k NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^l University of Ulsan   (South Korea)

^m Chungbuk National University Hospital   (South Korea)

ⁿ TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^o CHIANG MAI UNIVERSITY   (Thailand)

^p DEPARTMENT OF PATHOLOGY   (United States)

^q NONE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; LIOTHYRONINE; RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; THYROGLOBULIN; THYROTROPIN; THYROXINE;

ARTICLE; ASIA; ASPIRATION BIOPSY; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER PATIENT; CANCER SURGERY; CELL DIFFERENTIATION; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; EPITHELIOID CELL; EPITHELIUM CELL; ETHNIC DIFFERENCE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE AVAILABILITY; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PACIFIC ISLANDS; PATIENT CARE; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RACE DIFFERENCE; THYROID CANCER; THYROID CARCINOMA; THYROID FUNCTION TEST; THYROID SURGERY; THYROIDECTOMY;

ANTINEOPLASTIC AGENTS; ASIA; CELL DIFFERENTIATION; ENDOCRINOLOGY; FEMALE; HUMANS; MALE; NEOPLASMS, GLANDULAR AND EPITHELIAL; THYROID NEOPLASMS;

EID: 33745190962     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2006.16.461     Document Type: Article

References (22)

1. Globoscan Cancer Registry Data, 2002. www-dep.iarc.fr/ (Last accessed April 23, 2006).
2. Cancer Facts and Figures 2003. American Cancer Society, Atlanta, GA: 2003. www.cancer.org/downloads/STT/CAFF2003PWSecured.pdf (Last accessed April 23, 2006.)
3. Mazzaferri EL, Jhiang SM 1994 Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418-428.
4. rd 1998 Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer 83:1012-1021.
5. Demers LM, Spencer CA 2003 Laboratory medicine practice guidelines: Laboratory support for the diagnosis and monitoring of thyroid disease. Clin Endocrinol (Oxf) 58:138-140.
6. Ladenson PW, Braverman LE, Mazzaferri EL, Robbins J, Cooper DS, Garber JS, Wondisford FE, Davies TF, DeGroot LJ, Daniels GH, Ross DS, Levis S, Hay ID, McEllin K, Moscicki R, Weintraub BD 1997 Comparison of recombinant human thyrotropin administration to thyroid hormone withdrawal for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 337:888-896.
7. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, Cooper DS, Samuels M, Graham K, Braverman LE, Skarulis M, Davies TF, DeGroot LJ, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Becker DV, Maxon HR, Cavalieri RR, Spencer CA, McEllin K, Weintraub BD, Ridgway EC 1999 A comparison of recombinant thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 84:3877-3885.
8. Sutton RT, Reading CC, Charboneau JW, James EM, Grant CS, Hay ID 1988 US-guided biopsy of neck masses in postoperative management of patients with thyroid cancer. Radiology 168:769-772.
9. Larson SM, Robbins R 2002 Positron emission tomography in thyroid cancer management. Semin Roentgenol 37: 169-174.
10. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI, Tuttle RM; The American Thyroid Association Guidelines Taskforce 2006 Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16:109-142.
11. Thyroid Carcinoma Taskforce 2001 AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology. Endocr Pract 7:202-220.
12. Kendall-Taylor P; Guidelines Working Group 2003. Guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf) 58:400-402.
13. Chia KS, Seow A, Lee HP, Shanmugaratnam K 2000 Cancer incidence in Singapore 1993-1997. Singapore Cancer Registry Report No. 5.
14. Nam-Goong IS, Kim HY, Gong G, Lee HK, Hong SJ, Kim WB, Shong YK 2004 Ultrasonography-guided fine-needle aspiration of thyroid incidentaloma: Correlation with pathological findings. Clin Endocrinol (Oxf) 60:21-28.
15. Laboratory support for the diagnosis and monitoring of thyroid disease. National Academy of Clinical Biochemistry (NACB) 2002 NACB: laboratory support for the diagnosis and monitoring of thyroid disease. National Academy of Clinical Biochemistry (NACB), Washington, D.C.
16. Spencer CA 2000 Serum thyroglobulin measurements: clinical utility and technical limitations in the management of patients with differentiated thyroid carcinomas. Endocr Pract 6:481-484.
17. Asari S, Amino N, Horikawa M, Miyai K 1989 Incidences of antibodies to Yersinia enterocolitica: High incidence of serotype O5 in autoimmune thyroid diseases in Japan. Endocrinol Jpn 36:381-386.
18. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, Haugen BR, Sherman SI, Cooper DS, Braunstein GD, Lee S, Davies TF, Arafah BM, Ladenson PW, Pinchera A 2003 A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 88:1433-1441.
19. Pluijmen MJ, Eustatia-Rutten C, Goslings BM, Stokkel MP, Arias AM, Diamant M, Romijn JA, Smit JW 2003 Effects of low iodide diet on post-surgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 58:428-435.
20. Moog F, Linke R, Manthey N, Tiling R, Knesewitsch P, Tatsch K, Hahn K 2000 Influence of thyroid-stimulating hormone levels on uptake of FDC in recurrent and metastatic differentiated thyroid carcinoma. J Nucl Med 41:1989-1995.
21. Chin BB, Patel P, Cohade C, Ewertz ME, Wahl RL, Ladenson PW 2004 Recombinant human TSH stimulation of FDC PET uptake in well-differentiated thyroid Carcinoma. J Clin Endocrinol Metab 89:91-95.
22. Thyroid 2002 In: American Joint Committee on Cancer: AJCC Cancer Staging Manual, 9th ed. Springer, New York, pp. 77-87.